Evidence-Based Cardiology in Hemodialysis Patients

被引:37
作者
Allon, Michael [1 ]
机构
[1] Univ Alabama Birmingham, Div Nephrol, Birmingham, AL 35294 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2013年 / 24卷 / 12期
关键词
CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; SIROLIMUS-ELUTING STENTS; ALL-CAUSE MORTALITY; QUALITY-OF-LIFE; ATRIAL-FIBRILLATION; CARDIOVASCULAR EVENTS; DIALYSIS PATIENTS; ONLINE HEMODIAFILTRATION;
D O I
10.1681/ASN.2013060632
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cardiac events are the major cause of death in hemodialysis patients. Because of the paucity of randomized clinical trials (RCTs) in hemodialysis patients, most cardiovascular therapies in this population are based on observational studies or results extrapolated from studies that excluded hemodialysis patients. However, associations discovered in observational studies do not prove causality, and these studies often report surrogate outcomes rather than clinical end points. Furthermore, interventions that show effectiveness in the general population may have drastically different outcomes and side effect profiles in hemodialysis patients. This review discusses the results of RCTs undertaken recently to evaluate cardiovascular therapies in hemodialysis patients and emphasizes clinically relevant outcomes. Although some interventions have produced similar outcomes in hemodialysis patients and the general population, others have not, suggesting that the management of cardiovascular disease in hemodialysis patients may require strategies that differ from the best practice guidelines applied to general population.
引用
收藏
页码:1934 / 1943
页数:10
相关论文
共 91 条
[1]   The Controversies of Diagnosing and Treating Hypertension among Hemodialysis Patients [J].
Agarwal, Rajiv .
SEMINARS IN DIALYSIS, 2012, 25 (04) :370-376
[2]   Preventing Stroke and Systemic Embolism in Renal Patients with Atrial Fibrillation: Focus on Anticoagulation [J].
Ahmad, Yousif ;
Lip, Gregory Y. H. .
BRAIN, STROKE AND KIDNEY, 2013, 179 :81-91
[3]  
[Anonymous], KIDNEY INT
[4]   The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial [J].
Baigent, Colin ;
Landray, Martin J. ;
Reith, Christina ;
Emberson, Jonathan ;
Wheeler, David C. ;
Tomson, Charles ;
Wanner, Christoph ;
Krane, Vera ;
Cass, Alan ;
Craig, Jonathan ;
Neal, Bruce ;
Jiang, Lixin ;
Hooi, Lai Seong ;
Levin, Adeera ;
Agodoa, Lawrence ;
Gaziano, Mike ;
Kasiske, Bertram ;
Walker, Robert ;
Massy, Ziad A. ;
Feldt-Rasmussen, Bo ;
Krairittichai, Udom ;
Ophascharoensuk, Vuddidhej ;
Fellstrom, Bengt ;
Holdaas, Hallvard ;
Tesar, Vladimir ;
Wiecek, Andrzej ;
Grobbee, Diederick ;
de Zeeuw, Dick ;
Gronhagen-Riska, Carola ;
Dasgupta, Tanaji ;
Lewis, David ;
Herrington, William ;
Mafham, Marion ;
Majoni, William ;
Wallendszus, Karl ;
Grimm, Richard ;
Pedersen, Terje ;
Tobert, Jonathan ;
Armitage, Jane ;
Baxter, Alex ;
Bray, Christopher ;
Chen, Yiping ;
Chen, Zhengming ;
Hill, Michael ;
Knott, Carol ;
Parish, Sarah ;
Simpson, David ;
Sleight, Peter ;
Young, Alan ;
Collins, Rory .
LANCET, 2011, 377 (9784) :2181-2192
[5]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[6]   The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions [J].
Best, PJM ;
Lennon, R ;
Ting, HH ;
Bell, MR ;
Rihal, CS ;
Holmes, DR ;
Berger, PB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (07) :1113-1119
[7]   Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients [J].
Block, G. A. ;
Raggi, P. ;
Bellasi, A. ;
Kooienga, L. ;
Spiegel, D. M. .
KIDNEY INTERNATIONAL, 2007, 71 (05) :438-441
[8]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[9]   Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[10]   Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation [J].
Chan, Kevin E. ;
Lazarus, J. Michael ;
Thadhani, Ravi ;
Hakim, Raymond M. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (10) :2223-2233